A61P 27 - Drugs for disorders of the senses

Patents for A61P 27 - Drugs for disorders of the senses (53,017)
10/2011
10/27/2011	US20110263587 Reversibly heat-gelable aqueous composition
10/27/2011	US20110263583 Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1
10/27/2011	US20110263582 Cyclic urea inhibitors of 11 b-hydroxysteroid dehydrogenase 1
10/27/2011	US20110263574 Pirenzepine as otoprotective agent
10/27/2011	US20110263567 Compounds for inhibiting semicarbazide-sensitive amine oxidase (ssao) / vascular adhesion protein-1 (vap-1) and uses thereof for treatment and prevention of diseases
10/27/2011	US20110263561 Novel pyrrolidone derivatives for use as MetAP-2 inhibitors
10/27/2011	US20110263551 Method for treating otitis externa
10/27/2011	US20110263539 Ship 1 modulator compounds
10/27/2011	US20110263519 Regulators of the hedgehog pathway, compositions and uses related thereto
10/27/2011	US20110263494 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof
10/27/2011	US20110263483 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/27/2011	US20110263479 Peptides
10/27/2011	US20110262544 Ophthalmic administration of a composition including brimonidine as a mist
10/27/2011	US20110262534 polysaccharide capsule enclosing a fatty acid oil-containing emulsion
10/27/2011	US20110262519 Method of improving lens rotation
10/27/2011	US20110262517 Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
10/27/2011	US20110262511 Novel Uses
10/27/2011	US20110262432 mutated netrin 4 proteins, fragments thereof and their uses as drugs
10/27/2011	US20110262407 Treatment with alpha7 selective ligands
10/27/2011	US20110262368 C21 thioethers as glucocorticoid receptor agonists
10/26/2011	EP2380877A1 Pyridine-3-carboxyamide derivative
10/26/2011	EP2380872A1 Polycationic compounds and uses thereof
10/26/2011	EP2380632A1 The use of NMDA antagonists to attenuate vitreoretinal vascular endothelial growth factor (VEGF) protein levels in animals
10/26/2011	EP2380574A1 Eslicarbazepine acetate and methods of use
10/26/2011	EP2379109A1 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
10/26/2011	EP2379080A1 Pirenzepine as otoprotective agent
10/26/2011	EP2379078A2 Topical formulations of flap inhibitors for administration to an eye
10/26/2011	EP2379066A1 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
10/26/2011	EP1864994B1 Par-2 agonist
10/26/2011	EP1425010B1 Substituted indoles and their use as integrin antagonists
10/26/2011	CN102227409A Pyridine-3-carboxyamide derivative
10/26/2011	CN102225201A New application of glycolytic inhibitor
10/26/2011	CN102225194A Use of Bv8 and/or EG-VEGF to promote hematopoiesis
10/26/2011	CN102225178A Fructus galangae extract and medicinal application thereof
10/26/2011	CN102225160A Traditional Chinese preparation for treating Menieres disease
10/26/2011	CN102225136A Chinese medicinal composition for treating acute conjunctivitis and preparation method thereof
10/26/2011	CN102225087A Xanthophyll compound preparation with powerful eye-protecting effect
10/26/2011	CN101048166B Abnormal protein removing composition
10/25/2011	US8044182 Adiponectin and uses thereof
10/25/2011	US8044042 Thienotriazolodiazepine compound and medicinal use thereof
10/25/2011	US8044040 e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/25/2011	US8043831 Therapeutic agents comprising pro-apoptotic proteins
10/25/2011	US8043628 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
10/25/2011	CA2608163C Hydralazine compositions and methods
10/25/2011	CA2484020C Re-epithelializing pharmaceutical compositions comprising xanthan gum
10/20/2011	WO2011130462A2 Intraocular pressure reduction with intracameral bimatoprost implants
10/20/2011	WO2011130411A1 Compositions and methods for treating visual disorders
10/20/2011	WO2011130356A2 Systems and methods for activating cross-linking in an eye
10/20/2011	WO2011129461A1 Method and ophthalmic composition for treating retinal disease
10/20/2011	WO2011129424A1 Pharmaceutical agent for prevention and/or treatment of htlv-1-associated myelopathy
10/20/2011	WO2011127567A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	WO2011127565A1 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
10/20/2011	WO2011063394A3 Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
10/20/2011	US20110258713 Compositions and methods for re-programming cells without genetic modification
10/20/2011	US20110257601 Vegf antagonist formulations for intravitreal administration
10/20/2011	US20110257271 Derivatives of dimethylcurcumin
10/20/2011	US20110257266 Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated
10/20/2011	US20110257248 RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
10/20/2011	US20110257246 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
10/20/2011	US20110257238 Heteroaryl Dihydroindolones as Kinase Inhibitors
10/20/2011	US20110257233 Benzoisothiazolones as inhibitors of phosphomannose isomerase
10/20/2011	US20110257232 Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
10/20/2011	US20110257223 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
10/20/2011	US20110257222 Compounds and methods for the treatment of pain and other diseases
10/20/2011	US20110257214 Morphinan compounds
10/20/2011	US20110257208 Compounds useful as faah modulators and uses thereof
10/20/2011	US20110257188 Compositions and methods for the treatment of nasal conditions
10/20/2011	US20110257186 Compositions and methods for treating visual disorders
10/20/2011	US20110257179 Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
10/20/2011	US20110257175 Selected Inhibitors of Protein Tyrosine Kinase Activity
10/20/2011	US20110257170 4-morpholino-pyrido[3,2-d]pyrimidines
10/20/2011	US20110257163 Gamma secretase modulators
10/20/2011	US20110257137 Heterocyclic inhibitors of histamine receptors for the treatment of disease
10/20/2011	US20110257136 Ophthalmic Formulations Of Cetirizine And Methods Of Use
10/20/2011	US20110257125 Mucomimetic compositions and uses therefore
10/20/2011	US20110257105 Synthetic peptide amides and dimers thereof
10/20/2011	US20110257103 Compositions and methods for the treatment of sj?rgren's syndrome
10/20/2011	US20110257100 Inhibitors of Protein Tyrosine Kinase Activity
10/20/2011	US20110256186 biomaterial based on wharton's jelly from the human umbilical cord
10/20/2011	US20110256185 Reinforced tissue shields
10/20/2011	US20110256159 Adherent cells from placenta tissue and use thereof in therapy
10/20/2011	US20110256156 TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
10/20/2011	US20110256150 Modulation of Axon Degeneration
10/20/2011	US20110256130 Methods of treating inflammatory disorders
10/20/2011	US20110256122 Polypeptides, antibody variable domains & antagonists
10/20/2011	US20110256066 Method for preparing engineered mg doped ferrite superparamagnetic nano particle exhibiting ac magnetic induction heating at high temperature and mg doped ferrite superparamagnetic nano particles engineered by the method
10/20/2011	US20110256064 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
10/20/2011	US20110256054 Compositions and Methods for the Treatment and Prevention of Lens Fibrotic Diseases
10/20/2011	CA2796345A1 Compositions and methods for treating visual disorders
10/20/2011	CA2796054A1 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
10/20/2011	CA2796008A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	CA2795723A1 Method and ophthalmic composition for treating retinal disease
10/19/2011	EP2377875A1 Antioxidant
10/19/2011	EP2377874A1 Antioxidant
10/19/2011	EP2377553A1 Use of IL-1 antibodies for treating ophthalmic disorders
10/19/2011	EP2221377B1 Oligonucleotide compositions with enhanced efficiency
10/19/2011	EP1957451B1 Soft anticholinergic zwitterions
10/19/2011	EP1948596B1 Soft anticholinergic esters
10/19/2011	EP1499613B1 Thioxanthine derivatives as myeloperoxidase inhibitors
10/19/2011	EP1482931B1 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage

1 ... 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 ... 531